This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In a webinar broadcast on 28 February, Prof. Health Populi’s Hot Points: Some of that evidence is being generated right now through the deployment of care at home channeled through Best Buy Health, which Deborah Di Sanzo discussed in the webinar. That’s a strong business model and habit that’s hard to break.
We are promoting important dialogue and education across the industry, posting information and resources shared by members on the ATA website, and facilitating dozens of media requests, giving our members a public platform to discuss the value of telehealth and the technology-enabled solutions that are being implemented.
The FDA held a webinar earlier in the year to describe efforts to speed up the process of regulatory approval for automated insulin delivery systems. An initial 11-day trial in a real world setting proved the insulin-and-glucagon system’s safety and effectiveness. (If If the iLet gets approved, will it be an artificial pancreas?
In a webinar discussing implications from this research, Richard Edelman discussed Americans’ concerns about the growing role of AI in health care as part of this uptick in worry, saying that “AI is not automatically good,” noting potential risks to costs (increasing) as well as privacy.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content